AI Approach Helps Classify Alzheimer s Disease with Improved Accuracy azorobotics.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from azorobotics.com Daily Mail and Mail on Sunday newspapers.
E-Mail
(Boston) Warning signs for Alzheimer s disease (AD) can begin in the brain years before the first symptoms appear. Spotting these clues may allow for lifestyle changes that could possibly delay the disease s destruction of the brain. Improving the diagnostic accuracy of Alzheimer s disease is an important clinical goal. If we are able to increase the diagnostic accuracy of the models in ways that can leverage existing data such as MRI scans, then that can be hugely beneficial, explained corresponding author Vijaya B. Kolachalama, PhD, assistant professor of medicine at Boston University School of Medicine (BUSM).
Using an advanced AI (artificial intelligence) framework based on game theory (known as generative adversarial network or GAN), Kolachalama and his team processed brain images (some low and high quality) to generate a model that was able to classify Alzheimer s disease with improved accuracy.
Kansas woman s YouTube home show reveals our secret : Her husband, 43, has dementia Eric Adler, The Kansas City Star
Mar. 14 A wife, a mother, a nurse, Leslie Weiser of Bonner Springs kept what she called our secret to herself for months involving, as it did, the private life of her husband, Jason, whom she has loved since she was in high school.
Until Feb. 20 of last year, in fact, there was nothing on her new, self-produced YouTube channel, A Charming Abode With Leslie Weiser, to suggest it was about anything other than what it said it was: a suburban mom with an eye for decorating, offering tips for making a house a home. Her following in the beginning was modest.
Doanh nghiệp tuần qua: Lộ diện những khoản chia thưởng cao của năm 2020 ndh.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndh.vn Daily Mail and Mail on Sunday newspapers.
Thomson Reuters
But the drug missed most of the secondary trial goals, including one watched by experts.
An Eli Lilly executive told Insider the data was mixed, but very exciting.
The latest test of Eli Lilly s Alzheimer s disease drug ended with a mixed bag of results that disappointed investors.
Lilly gave an in-depth look at the performance of its drug, called donanemab, on Saturday at the International Conference on Alzheimer s and Parkinson s Diseases. The drug met the trial s primary goals, reducing a harmful substance that builds up in the brains of patients with Alzheimer s disease. It also slowed down the rate of cognitive decline by 32%, according to data published Saturday in a medical journal. But it missed the mark on several secondary tests.